73.57

0.77% 0.56

After Hours: 73.89 0.32 +0.43%

Ptc Therapeutics Inc (PTCT)

Overview News Price History Option Chain Financials Why PTCT Down? Discussions Forecast

Ptc Therapeutics Inc stock is traded at $73.57, with a volume of 568.76K. It is up +0.77% in the last 24 hours and up +14.08% over the past month. PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Previous Close:

$73.01

Open:

$73.15

24h Volume:

568.76K

Relative Volume:

0.50

Market Cap:

$6.09B

Revenue:

$1.73B

Net Income/Loss:

$682.64M

P/E Ratio:

9.5096

EPS:

7.7364

Net Cash Flow:

$411.18M

1W Performance:

+3.24%

1M Performance:

+14.08%

6M Performance:

+7.39%

1Y Performance:

+56.73%

1-Day Range:

$72.20

$73.69

1-Week Range:

$68.22

$73.79

52-Week Range:

$35.95

$87.50

Ptc Therapeutics Inc Stock (PTCT) Company Profile

Name

Ptc Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(908) 222-7000

Address

500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ

Employee

991

Twitter

@PTCBio

Next Earnings Date

2024-11-07

Latest SEC Filings

PTCT's Discussions on Twitter

Compare PTCT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTCT Ptc Therapeutics Inc	73.57	6.04B	1.73B	682.64M	411.18M	7.7364
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Raymond James	Outperform
Jan-28-26	Resumed	Barclays	Overweight
Dec-01-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Oct-20-25	Initiated	Wells Fargo	Overweight
Jun-17-25	Initiated	Truist	Buy
May-09-25	Upgrade	BofA Securities	Neutral → Buy
May-07-25	Upgrade	Citigroup	Sell → Neutral
Mar-11-25	Upgrade	BofA Securities	Underperform → Neutral
Mar-07-25	Initiated	Scotiabank	Sector Perform
Dec-13-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-03-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-10-24	Resumed	Raymond James	Mkt Perform
Sep-04-24	Initiated	Robert W. Baird	Outperform
Aug-26-24	Resumed	UBS	Buy
May-20-24	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Dec-08-23	Initiated	Wells Fargo	Overweight
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform
Oct-27-23	Downgrade	Citigroup	Neutral → Sell
Oct-06-23	Downgrade	Truist	Buy → Hold
Sep-18-23	Downgrade	Citigroup	Buy → Neutral
Sep-15-23	Downgrade	Raymond James	Outperform → Underperform
Mar-17-23	Initiated	SVB Securities	Market Perform
Dec-14-22	Initiated	Goldman	Sell
Sep-12-22	Initiated	Jefferies	Buy
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
Sep-01-22	Initiated	Citigroup	Buy
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight
Oct-18-21	Downgrade	BofA Securities	Neutral → Underperform
Apr-26-21	Resumed	Credit Suisse	Neutral
Mar-29-21	Upgrade	RBC Capital Mkts	Underperform → Sector Perform
Feb-12-21	Downgrade	BofA Securities	Buy → Neutral
Jan-05-21	Upgrade	Citigroup	Neutral → Buy
Nov-30-20	Downgrade	RBC Capital Mkts	Sector Perform → Underperform
Oct-30-20	Downgrade	Citigroup	Buy → Neutral
Oct-28-20	Initiated	UBS	Neutral
Oct-07-20	Upgrade	JP Morgan	Neutral → Overweight
Aug-25-20	Initiated	Raymond James	Outperform
Apr-09-20	Upgrade	Citigroup	Neutral → Buy
Feb-20-20	Downgrade	Citigroup	Buy → Neutral
Feb-20-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-12-19	Initiated	SunTrust	Buy
May-13-19	Upgrade	BofA/Merrill	Neutral → Buy
Apr-11-19	Initiated	Bernstein	Outperform
Oct-03-18	Upgrade	BofA/Merrill	Underperform → Neutral
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Jul-19-18	Initiated	Credit Suisse	Outperform
Jun-18-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Apr-04-18	Downgrade	Barclays	Equal Weight → Underweight
Jan-29-18	Resumed	RBC Capital Mkts	Sector Perform
Nov-16-17	Upgrade	JP Morgan	Underweight → Neutral
Oct-26-17	Downgrade	BofA/Merrill	Neutral → Underperform
Oct-09-17	Downgrade	JP Morgan	Neutral → Underweight

View All

Ptc Therapeutics Inc Stock (PTCT) Latest News

08:56 AM

Yousif Capital Management LLC Buys Shares of 22,228 PTC Therapeutics, Inc. $PTCT - MarketBeat

08:56 AM

Apr 14, 2026

24,524 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Ritholtz Wealth Management - MarketBeat

Apr 14, 2026

Burney Co. Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat

Apr 14, 2026

Apr 13, 2026

Raymond James Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $86 - Moomoo

Apr 13, 2026

Is It Time To Reassess PTC Therapeutics (PTCT) After Its Strong One Year Rally? - Sahm

Apr 13, 2026

Apr 12, 2026

PTCT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 12, 2026

B of A Securities Lowers Price Target for PTC Therapeutics (PTCT) to $93 | PTCT Stock News - GuruFocus

Apr 12, 2026

Apr 11, 2026

(PTCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Apr 11, 2026

PTC Therapeutics (NASDAQ:PTCT) Stock Rating Upgraded by Raymond James Financial - MarketBeat

Apr 11, 2026

Apr 10, 2026

Treasury Yields: Will PTC Therapeutics Inc benefit from current market trends2026 Sector Review & Free Daily Entry Point Trade Alerts - baoquankhu1.vn

Apr 10, 2026

PTC Therapeutics (NASDAQ:PTCT) Now Covered by Analysts at Raymond James Financial - MarketBeat

Apr 10, 2026

Is PTC Therapeutics Inc attractive for institutional investors2026 Review & Safe Swing Trade Setup Alerts - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Raymond James initiates PTC Therapeutics stock coverage with outperform rating By Investing.com - Investing.com South Africa

Apr 09, 2026

Raymond James initiates PTC Therapeutics stock coverage with outperform rating - Investing.com

Apr 09, 2026

Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120 - Moomoo

Apr 09, 2026

Apr 08, 2026

PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,265 Shares - MarketBeat

Apr 08, 2026

PTC Therapeutics exec VP Boulding sells $157k in shares By Investing.com - Investing.com Canada

Apr 08, 2026

PTC Therapeutics (PTCT) EVP trades options and sells 2,265 shares - Stock Titan

Apr 08, 2026

Apr 07, 2026

RBC Adjusts Price Target on PTC Therapeutics to $81 From $82, Maintains Sector Perform Rating - Moomoo

Apr 07, 2026

RBC Capital Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Cuts Target Price to $81 - Moomoo

Apr 07, 2026

Duchenne Muscular Dystrophy Therapeutics Market to Reach USD - openPR.com

Apr 07, 2026

Apr 06, 2026

Insider Selling: PTC Therapeutics (NASDAQ:PTCT) EVP Sells 829 Shares of Stock - MarketBeat

Apr 06, 2026

Golden Lee, PTC Therapeutics EVP, sells $56k in shares By Investing.com - Investing.com Australia

Apr 06, 2026

PTC Therapeutics (PTCT) CMO executes 829-share tax sell-to-cover - Stock Titan

Apr 06, 2026

PTCT (NASDAQ: PTCT) Form 144: Insider proposes sale of 2,265 shares - Stock Titan

Apr 06, 2026

PTCT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Apr 06, 2026